The association between therapeutic outcomes and VEGF G-1154A and C-936T gene polymorphisms in patients with glomerulonephritis

Figures & data

Figure 1. Genotyping of VEGF gene C-936T polymorphisms. Lane 1 and 4: C/T genotype (208, 122, and 86 bp), Lane 2: T/T genotype (122 and 86 bp), Lane 3 and 5: C/C genotype (208 bp).

Figure 2. Genotyping of vascular endothelial growth factor (VEGF) gene G-1154A polymorphisms. Lane 1 and 2: G/A genotype (184, 150, 34, 22, and 86 bp), Lane 3 and 4: A/A genotype (184 and 22 bp), Lane 5: G/G genotype (150, 34, and 22 bp).

Table 1. The baseline characteristics of the patients.

	Group 1 (n = 18)	Group 2 (n = 20)	p Value
Age (years) (mean ± SD)	35.8 ± 14	37.3 ± 14	0.838
Gender (M/F)	9/9	7/13	0.350
Body weight (kg) (mean ± SD)	73.00 ± 11	71.5 ± 12	>0.05
Smoking	4 (22.2%)	2 (10%)	>0.05
Hypertension	5 (27.8%)	6 (30%)	>0.05
Diabetes mellitus	1 (5.6%)	1 (5%)	>0.05

Table 2. The percentage of histopathological diagnosis of the patients.

Diagnosis	n (%)
IgA nephropathy	7 (18.4)
Membranous glomerulonephritis	11 (28.9)
Membranoproliferative glomerulonephritis	6 (15.8)
Focal segmental glomerulosclerosis	4 (10.5)
Lupus nephritis^a	3 (7.9)
Rapidly progressive glomerulonephritis	2 (5.2)
IgG nephropathy	1 (2.6)
IgM mesangial proliferative glomerulonephritis	2 (5.2)
c-ANCA positive glomerulonephritis	2 (5.2)
Total	38 (100)

Note: ^aOf the three patients, two had diffuse proliferative lupus nephritis, and one had focal proliferative lupus nephritis.

Table 3. The comparison groups in terms of VEGF C-936T gene polymorphisms.

VEGF C-936T gene polymorphism	Group 1 (n = 18)	Group 2 (n = 20)	p Value
CC	13 (72.2)	16 (80)	0.763
CT	3 (16.7)	3 (15)
TT	2 (11.1)	1 (5)

Table 4. The comparison groups in terms of VEGF G-1154A gene polymorphisms.

VEGF G-1154A gene polymorphism	Group 1 (n = 18)	Group 2 (n = 20)	p Value
AA	2 (11.1)	0 (0)	0.061
GA	12 (66.7)	9 (45)
GG	4 (22.2)	11 (55)